NY Times

SEPTEMBER 8, 2020

The company halted late-stage trials of its coronavirus vaccine because of a serious suspected adverse reaction in a participant.

Adverse Reactions 98

Adverse Reactions Vaccines 98

Express Pharma

JANUARY 16, 2024

“It is a known adverse reaction of many drugs…When prescribing any medicine, doctors take patient history and other individual factors into account to reduce the risk of any adverse reaction,” the statement said.

Adverse Reactions 105

Adverse Reactions Documentation 105

The Pharmacist

OCTOBER 25, 2024

Healthcare professionals should also ensure patients are aware of the side-effects of the diabetes and weight loss injections and report any adverse reactions through the Yellow Card reporting scheme, the Medicines and Healthcare […] The post MHRA urges pharmacists to be alert to signs of GLP-1 RA ‘misuse’ appeared first on The Pharmacist.

Adverse Reactions 93

Adverse Reactions Diabetes 93

The Pharmacist

APRIL 26, 2023

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a reminder to healthcare professionals about possible adverse reactions to nitrofurantoin.

Adverse Reactions 98

Adverse Reactions 98

Pharmacy Times

JULY 5, 2024

Alan Chin, PharmD, BCOP, presents an overview of the most prevalent and common adverse reactions associated with EGFR-targeted therapies in metastatic NSCLC and shares strategies to mitigate toxicities, with a focus on managing dermatologic events such as rash and itching.

Adverse Reactions 26

Adverse Reactions 26

STAT

SEPTEMBER 7, 2022

 Moving forward, the company will expand patient monitoring in the trial to watch for low magnesium levels, which had resulted in a serious adverse reaction in one study participant that led the FDA to suspend testing earlier this year. Food and Drug Administration on changes to the study’s plan , BioPharma Dive writes. Moving

Adverse Reactions 130

Adverse Reactions Vaccines 130

Pharmaceutical Technology

MAY 19, 2023

Blurred vision and eye redness are the most common adverse reactions observed with Miebo. The two 57-day, double-masked, multi-centre, saline-controlled, randomised trials were conducted in 1,217 people with DED history and clinical signs of Meibomian gland dysfunction, a major cause of development and disease progression.

Adverse Reactions 133

Adverse Reactions 133

Pharmacy Times

JANUARY 4, 2024

This study showed the importance of a multidisciplinary team’s expertise to investigate a clinical inquiry beyond the scope of the clinicians’ skillset and their access to necessary technology.

Adverse Reactions 36

Adverse Reactions 36

pharmaphorum

DECEMBER 9, 2020

The most common adverse reactions seen in a trial cohort of 38,000 patients were at injection sites (84.1%) followed by fatigue (62.9%) and headache (55.1%), and serious adverse reactions occurred in 0% to 4.6% of participants.

Vaccines 111

Vaccines Adverse Reactions Documentation Immunization 111

Pharmaceutical Technology

JANUARY 13, 2023

Diarrhoea, decreased appetite, constipation, fatigue, musculoskeletal pain, neutropenia, vomiting, anaemia, leukopenia, thrombocytopenia, increased transaminases, nausea, and alopecia are the most common adverse reactions observed in the trial.

Adverse Reactions 128

Adverse Reactions Chemotherapy 128

European Pharmaceutical Review

NOVEMBER 21, 2022

The most common adverse reactions (ARs) in 10 percent or more of patients were respiratory tract infection (RTI), viral infection, diarrhoea, dyspepsia, cough, arthralgia, arthritis and peripheral edema. Serious adverse reactions (SARs) were reported in 13 percent (3/24) of patients who received the mAb.

Adverse Reactions 111

Adverse Reactions Labelling 111

Pharmaceutical Business Review

AUGUST 8, 2024

Common adverse reactions include feeling hot, dizziness, headache, nausea, palpitations, chills, vomiting, allodynia, tinnitus, ear discomfort, burning sensation, hot flush, feeling abnormal, and irritability.

Adverse Reactions 105

Adverse Reactions 105

Express Pharma

JULY 16, 2024

This new system uses an ionic buffer blend to keep ophthalmic solutions sterile while reducing adverse reactions, providing a safer and more effective option for long-term eye care. The EyeBS preservative system is a major advancement in ophthalmic care, formulated with borate, sorbitol, propylene glycol, and zinc.

Adverse Reactions 92

Adverse Reactions 92

European Pharmaceutical Review

JANUARY 18, 2023

To date, most solicited adverse reactions were mild or moderate. The most commonly reported solicited adverse reactions in the mRNA-1345 group were injection site pain, fatigue, headache, myalgia, and arthralgia. The trial showed the mRNA vaccine was well tolerated with no safety concerns identified.

Vaccines 105

Vaccines Adverse Reactions 105

Pharmacy Times

JUNE 20, 2023

A counterfeit medication was reportedly purchased at a retail pharmacy, appearing to have contained another type of diabetes medication that led to an adverse reaction.

Adverse Reactions 62

Adverse Reactions Diabetes 62

Express Pharma

NOVEMBER 26, 2023

Serious adverse reactions: Regarding serious adverse reactions (SARs), an interesting finding was made. On day 28, the higher-dose group’s risk of death was 8.3 per cent lower for patients in Europe, whereas there was essentially no difference (0.1 per cent) in India. While a larger percentage (-1.0 per cent).

Adverse Reactions 112

Adverse Reactions Diabetes Hospitals 112

European Pharmaceutical Review

OCTOBER 18, 2023

However, in the trials, the only observed adverse reaction for the treatment was diarrhoea. Overall, the data showed that XPHOZAH significantly reduced elevated serum phosphorus in patients receiving maintenance hemodialysis.

Adverse Reactions 119

Adverse Reactions Labelling 119

European Pharmaceutical Review

JULY 20, 2022

1 But while data on adverse reactions is rightly used to help with these decisions, there is currently no additional modelling on the positive impact regulatory action could have on public health. Withdrawing drugs over safety concerns requires careful analysis of the health benefits and risks by regulators. Study focus.

Adverse Reactions 97

Adverse Reactions Diabetes Hospitals Vaccines 97

pharmaphorum

JANUARY 18, 2021

While no vaccine or medical procedure is without risk, the risk of a serious adverse reaction is very small, according to the department. At last count, California had recorded almost 3 million COVID-19 cases, with just over 33,000 deaths, placing it among the worst affected states in the US.

Vaccines 136

Vaccines Adverse Reactions 136

PharmaTech

FEBRUARY 12, 2024

The agency’s safety committee stressed the risk of potential adverse reactions involved with taking Paxlovid (nirmatrelvir, ritonavir) in combination with certain immunosuppressants.

Adverse Reactions 52

Adverse Reactions 52

pharmaphorum

SEPTEMBER 10, 2020

That could be important if it takes longer than expected to bring vaccines and antibodies to market, said a spokesman for the companies, pointing to the news this week that AstraZeneca has halted phase 3 trials of its COVID-19 vaccine candidate AZD1222 after a serious adverse reaction in one patient.

Vaccines 133

Vaccines Adverse Reactions Immunization Immunity 133

Pharmaceutical Technology

MARCH 23, 2023

Diarrhoea, rash, pyrexia, nausea, musculoskeletal pain, fatigue and pruritus are the most common adverse reactions observed in patients treated with Zynyz. Partial response was seen in 22 patients and complete response in 12 patients.

Adverse Reactions 98

Adverse Reactions Compounding Chemotherapy Labelling 98

pharmaphorum

OCTOBER 26, 2020

US trials of AstraZeneca’s experimental COVID-19 vaccine AZD1222 have been cleared to restart by the FDA, several weeks after testing was suspended following a serious adverse reaction in one patient who received the shot.

Vaccines 95

Vaccines Adverse Reactions 95

LifeProNow

MARCH 10, 2023

The most common adverse reactions reported in at least 2% of patients treated with ZAVZPRET and at a frequency greater than placebo were taste disorders (includes dysgeusia and ageusia), nausea, nasal discomfort and vomiting. If a hypersensitivity reaction occurs, discontinue ZAVZPRET and initiate appropriate therapy.

Adverse Reactions 100

Adverse Reactions 100

PharmExec

JUNE 2, 2023

New program seeks to reduce misuse and adverse reactions by simplifying prescription labels.

Adverse Reactions 52

Adverse Reactions Labelling 52

Pharmaceutical Technology

MAY 23, 2023

Dizziness, flushing, eye oedema and peripheral oedema are the most common adverse reactions for Ayvakit. Ayvakit showed improvements in disease symptoms and measures of mast cell burden compared to placebo. The company is now offering Ayvakit at a recommended 25mg once-a-day dose for adults with ISM.

Adverse Reactions 98

Adverse Reactions Labelling 98

Pharmaceutical Technology

FEBRUARY 5, 2023

Colitis, neutropenic colitis, diarrhoea, vomiting, neutropenia, febrile neutropenia, pneumonia, and abdominal pain are the most frequent serious adverse reactions observed in the TROPiCS-02 study. “We thank the physicians, patients and their families who put their trust in the TROPiCS-02 study and helped make this milestone possible.”

Adverse Reactions 105

Adverse Reactions Chemotherapy Labelling 105

Pharmaceutical Technology

JULY 6, 2022

Tenderness/pain at the injection site, headache, myalgia, fatigue and malaise were the most common adverse reactions reported. Furthermore, the vaccine was found to be well-tolerated in the initial safety findings from the study.

Vaccines 105

Vaccines Adverse Reactions 105

Pharmaceutical Technology

DECEMBER 7, 2022

A reduced number of serious and severe adverse reactions (AR) were reported and balanced between the vaccine and placebo arms. . Effectiveness was backed by clinical efficacy showing that the vaccine offered an overall 79.5% clinical protective efficacy when the Delta variant of the virus was prevalent.

Vaccines 105

Vaccines Adverse Reactions 105

Pharmaceutical Technology

NOVEMBER 25, 2022

Nausea, fatigue, vomiting, reduced neutrophil count, alopecia and anaemia among others were observed to be the most prevalent adverse reactions. The safety profile of Enhertu in this trial was in line with those seen in prior studies without any new safety concerns reported.

Adverse Reactions 105

Adverse Reactions Chemotherapy Labelling 105

European Pharmaceutical Review

NOVEMBER 23, 2022

The most common adverse reactions (AR) associated with Hemgenix included liver enzyme elevations (transaminitis), headache, mild infusion-related reactions and flu-like symptoms. Patients should be monitored for adverse infusion reactions and transaminitis in their blood.

Adverse Reactions 128

Adverse Reactions 128

Pharmaceutical Technology

FEBRUARY 20, 2023

Vitreous floaters, ocular discomfort, conjunctival hemorrhage, and neovascular AMD were the most common adverse reactions observed in patients receiving Syfovre. Syfovre’s safety profile is well-demonstrated after approximately 12,000 injections over 24 months.

Adverse Reactions 98

Adverse Reactions Immunization Immunity 98

Pharmaceutical Technology

MARCH 1, 2023

Rash pruritic, leukopenia, myalgia, injection site pruritus, neutropenia, fatigue, and constipation were the typical adverse reactions observed in the patients treated with Kevzara. The trial met its primary endpoint, with 28% of patients treated with Kevzara achieving sustained remission compared to 10% for placebo at 52 weeks.

Adverse Reactions 98

Adverse Reactions 98

European Pharmaceutical Review

NOVEMBER 13, 2023

In these clinical trials, the most common adverse reactions were diarrhoea, thrombocytopaenia, nausea, headache, dizziness, fatigue, asthenia, abdominal pain and cough. This trial aimed to evaluate the efficacy and safety of momelotinib versus ruxolitinib for myelofibrosis in those who had not received a prior JAK-inhibitor therapy.

Adverse Reactions 109

Adverse Reactions Pharmaceutical Companies Pharmaceutical Companies 109

European Pharmaceutical Review

JANUARY 8, 2024

Healthcare professionals are asked to report any suspected adverse reactions. . ▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. The post Innovative biologic for myasthenia gravis granted European approval appeared first on European Pharmaceutical Review.

Adverse Reactions 98

Adverse Reactions 98

Pharmacy Times

JANUARY 4, 2023

Children who experienced COVID-19-induced multisystem inflammatory syndrome did not experience severe adverse reactions following COVID-19 vaccination.

Adverse Reactions 49

Adverse Reactions Vaccines 49

European Pharmaceutical Review

JUNE 2, 2023

The new Intracellular Drug Delivery Centre CPI’s Intracellular Drug Delivery Centre will help predict the stability, efficacy, performance and any potential adverse reactions of RNA vaccines and therapeutics. This will help unlock the potential of RNA-based medicines, creating greater access to cost-effective vaccines and therapeutics.

Adverse Reactions 105

Adverse Reactions Vaccines Drug Development 105